Image pharmaphorum Editor Views & Analysis To unlock innovation, pharma needs to be honest about failur... Many successful leaders agree that a company’s willingness to embrace and learn from failure can unlock inn News Biogen’s Alzheimer’s drug, elenbecestat, shows early promise A trial of Biogen’s Alzheimer’s disease drug elenbecestat has had promising results in mild to moderate forms of the disease. Views & Analysis Patient centricity makes ethical and commercial sense Patient centricity is no longer a buzzword, it’s an essential way of conducting business that makes both ethical and commercial sense. Views & Analysis Disease spotlight: Duchenne muscular dystrophy (DMD) Load more results
Views & Analysis To unlock innovation, pharma needs to be honest about failur... Many successful leaders agree that a company’s willingness to embrace and learn from failure can unlock inn
News Biogen’s Alzheimer’s drug, elenbecestat, shows early promise A trial of Biogen’s Alzheimer’s disease drug elenbecestat has had promising results in mild to moderate forms of the disease.
Views & Analysis Patient centricity makes ethical and commercial sense Patient centricity is no longer a buzzword, it’s an essential way of conducting business that makes both ethical and commercial sense.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
